TAK-677: Dainippon/Takeda

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1624-1628

  Francke, Stephan ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (INDOL 3 YL)ETHYLAMINO] 1 PHENYLETHANOL DERIVATIVE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INDOLE DERIVATIVE; INSULIN; L 755507; L 796568; LEPTIN; TAK 677; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

BLOOD PRESSURE; CLINICAL TRIAL; DISEASE MODEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EXPOSURE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENERGY EXPENDITURE; GENE MUTATION; HEART RATE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREMOR;

ACETIC ACIDS; ADRENERGIC BETA-AGONISTS; ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; INDOLES; OBESITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036881829     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. 15123 Tremor and the anti-obesity drug BRL 26830A. Connacher AA, Lakie M, Powers N, Elton RA, Walsh EG, Jung RT Br J Clin Pharmacol 1990 30 4 613-615
2. 68381 Effects of BRL 26830, a novel β-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats Smith SA, Levy AL, Sennitt MV, Simson DL, Cawthorne MA Biochem Pharmacol 1985 34 14 2425-2429
3. 3-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Yoshida T, Yoshida N, Wakabayashi Y, Umekawa T, Kondo M Eur J Endocrinol 1994 131 1 97-102
4. 3-adrenergic responsiveness in rat adipocytes. Portillo MP, Barrio ASD, Angeles M, Martinez JA Life Sci 1996 58 5 405-414
5. 3-adrenergic receptor. Chaudhry A, Granneman JG J Pharmacol Exp Ther 1994 271 3 1253-1258
6. 3-adrenoceptors in obesity. Lonnqvist F, Thorne A, Nilsell K, Hoffstedt J, Arner P J Clin Invest 1995 95 3 1109-1116
7. 263369 214th American Chemical Society (ACS) Meeting (Part V); Highlights from medicinal chemistry poster session, Las Vegas, Nevada, USA. Berrie MS IDDB Meeting Report 1997 September 7-11
8. 3-adrenergic agonist: Synthesis and biological activity of indole derivatives. Harada H, Kato S, Kawashima H, Furutani Y ACS 1997 214th Las Vegas MEDI 208
9. 3-adrenoceptor agonist AD-9677. Kawashima H, Nomura A, Ohue M, Kato H, Kuwajima J, Furutani Y, Hosoki K Diabetologia 1997 40 Suppl 1 A374
10. 3-adrenoceptor agonist, in genetically obese diabetic mice. Kato H, Kiyoshi A, Fujitani B, Furutani Y, Hosoki K, Karasawa T Jpn J Pharmacol 1998 76 Suppl 1 Abs P-525
11. 315271 Pharmacological treatment of obesity: Therapeutic strategies Kordik CP, Reitz AB J Med Chem 1999 42 2 181-201
12. 343647 Dainippon, Takeda to codevelop new type of diabetes drug. Pharma Jpn 1999 1667 6
13. 371290 Dainippon and Takeda sign an agreement regarding a new anti-diabetic agent. Takeda Chemical Industries Ltd Press Release February 03
14. 393513 Annual report 2000: Dainippon. Dainippon Pharmaceutical Co Ltd Annual Report 2000 March 31
15. 402216 Annual report 2000: Takeda. Takeda Chemical Industries Ltd Annual Report 2000 March 31
16. 411811 Global healthcare bulletin. Merrill Lynch Capital Markets 2001 May 18
17. 3-adrenergic receptor angonist AJ9677 is mainly stimulated by the factor other than free fatty acids. Togahi M, Sakura H, Karibe S, Iwamoto Y Diabetes 2001 50 Suppl 6 Abs 1482-P
18. 416686 Cost reduction contributes to good performances: President Miyatake of Dainippon. Pharma Jpn 2001 1755 8
19. 423455 Annual Report 2001: Takeda Chemical Industries Inc. Takeda Chemical Industries Ltd Annual Report 2001 March 31
20. 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. De Souza CJ, Burkey BF Curr Pharm Design 2001 7 14 1433-1449
21. 3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model. Kato H, Ohue M, Kato K, Nomura A, Toyosawa K, Furutani Y, Kimura S, Kadowaki T Diabetes 2001 50 1 113-122. Comprehensive study in a rodent animal model, describing the effects of TAK-677 treatment on expression patterns of characteristic genes like UCP1, TNFα, leptin and GLUT4. The study shows the physiological and cytological effects of TAK-677 on fat tissue and the outcome on energy expenditure.
22. 3-AR agonists increase energy expenditure in humans, accompanied by an increase in plasma glycerol and free fatty acid concentration.
23. 452237 Body-mass index and mortality in a prospective cohort of US adults. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW N Engl J Med 1999 341 15 1097-1105
24. 452241 Obesity as a medical problem. Kopelman PG Nature 2002 404 6778 635-643
25. 452254 Medicinal strategies in the treatment of obesity. Bray GA, Tartaglia LA Nature 2002 404 6778 672-677
26. 452259 Dexfenfluramine bydrochloride: An anorexigenic agent. Bever KA, Perry PJ Am J Health-System Pharm 1997 54 18 2059-2072
27. 3-adrenergic stimulation of human thermogenesis and lipid use. Sciffelers SL, Blaak EE, Saris WH, Van Baak MA Clin Pharmacol Ther 2000 67 5 558-566
28. 3-adrenergic receptor mRNA in man. Krief S, Lonnqvist F, Raimbault S, Baude B, Van Spronsen A, Amer P, Stroberg AD, Ricquier D, Emorine LJ J Clin Invest 1993 91 1 344-349
29. 3-adrenergic receptor. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD Science 1989 245 4922 1118-1121
30. 452285 Antibodies for the immunochemistry of the human beta 3-adrenergic receptor. Guillaume JL, Petitjean F, Haasemann M, Bianchi C, Eshdat Y, Strosberg AD Eur J Biochem 1994 224 2 761-770
31. 3-adrenoceptor in man. Lonnqvist F, Krief S, Strosberg AD, Nyberg S, Emorine LJ, Arner P Br J Pharmacol 1993 110 929-936
32. 3-adrenoceptor in man. Enocksson S, Shimizu M, Lonnqvist F, Nordenstrom J, Arner P J Clin Invest 1995 95 5 2239-2245. ss3-AR co-exists with ss1- and ss2-adrenoceptors in adipose tissue and play a role in lipolysis regulation as shown in this ex vivo study of human adipose tissue.
33. 3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. Carpene C, Galitzky J, Collon P, Esclapez F, Dauzats M, Lafontan M J Pharmacol Exp Ther 1993 265 1 237-247
34. 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, Marullo S Mol Pharmacol 1993 43 4 548-555
35. 452378 The antiobesity and metabolic activities of LY79771 in obese and normal mice. Yen TT Int J Obesity 1984 8 1 69-78
36. 452384 ICI D7114: A novel selective adrenoceptor agonist of brown fat and thermogenesis. Holloway BR, Howe R, Rao BS, Stribling D Am J Clin Nutr 1992 55 1 Suppl 262S-264S
37. 3-adrenoceptors mediate metabolic responses to isoprenaline. Wheeldon NM, McDevitt DG, Lipworth BJ Q J Med 1993 86 9 595-600
38. 452404 Adrenoceptor subtypes mediating catecholamine-induced thermogenesis in man. Blaak EE, Saris WH, Van Baak MA Int J Obesity Relat Metab Disord 1993 17 Suppl 3 S78-S81
39. 3-AR.
40. 3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. Fisher MH, Metzger JM, Miller RR, Ok HO, Parmee ER, Saperstein R, Strader CD, Steams RA, MacIntyre DE J Clin Invest 1998 101 11 2387-2393
41. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD N Engl J Med 1995 333 6 352-354
42. 3-adrenergic-receptor gene. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N N Engl J Med 1995 333 6 343-347
43. 3-adrenoceptor gene polymorphism and β-blockers on triglyceride and HDL concentrations. Manraj M, Francke S, Hebe A, Ramjuttun US, Froguel P Diabetologia 2001 44 1 115-122
44. 3-adrenoceptor agonist in human omental adipocytes. Umekawa T, Yoshida T, Sakane N, Kogure A, Kondo M, Honjyo H Diabetes 1999 48 1 117-120
45. 3-adrenergic agonists in transfected 3T3-L1 preadipocytes. Kimura K, Sasaki N, Asano A, Mizukami J, Kayahashi S, Kawada T, Fushiki T, Morimatsu M, Yoshida T, Saito M Horm Metab Res 2000 32 3 91-96
46. 2-adrenoceptor blockade. Wheeldon NM, McDevitt DG, Lipworth BJ Br J Clin Pharmacol 1994 38 2 103-108
47. 452503 Energy expenditure, fat oxidation, and body weight regulation: A study of metabolic adaptation to long-term weight change. Weyer C, Pratley RE, Salbe AD, Bogardus C, Ravussin E, Tataranni PA J Clin Endocrinol Metab 2000 85 3 1087-1094
48. 452541 Mortality and weight: Insured lives and the American Cancer Society studies. Lew EA Ann Intern Med 1985 103 6 Pt 2 1024-1029
49. 453714 WO-09616938: Indole derivative. Kato S, Harada H, Hirokawa Y, Yoshida N, Kawashima H US PATENT 1997 October 15
50. 456438 Takeda Chemical - Growth prospects a concern. Suzuki J, Sakamoto C HSBC 2002 April 11
51. 458312 Takeda Chemical Industries. Barker S, Hatakenaka Y UBS Warburg (Japan) 2002 June 18
52. 458750 Annual Report 2001: Dainippon Pharmaceutical Co Ltd. Dainippon Pharmaceutical Co Ltd Annual Report 2001 March 31